{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:32:45Z","timestamp":1787319165646,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jaip.2019.04.030","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T05:42:14Z","timestamp":1567662134000},"page":"2396-2397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Omalizumab and Mast Cell Disorders: Are We There Yet?"],"prefix":"10.1016","volume":"7","author":[{"given":"Catherine R.","family":"Weiler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.04.030_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.iac.2004.06.002","article-title":"Anti-IgE therapy","volume":"24","author":"Brownell","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.04.030_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fmed.2017.00152","article-title":"Anti-IgE treatment for disorders other than asthma","volume":"4","author":"Stokes","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2019.04.030_bib3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.04.030_bib4","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1398-9995.2009.02045.x","article-title":"Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis","volume":"64","author":"Kontou-Fili","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.04.030_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACI.0b013e32833b280c","article-title":"Mastocytosis and insect venom allergy","volume":"10","author":"Bonadonna","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.04.030_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.04.030_bib7","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.04.030_bib8","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaip.2018.07.041","article-title":"Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis","volume":"7","author":"Constantine","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.04.030_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.04.030_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ced.13408","article-title":"Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair\u00ae)","volume":"43","author":"Hughes","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2019.04.030_bib11","doi-asserted-by":"crossref","first-page":"e12848","DOI":"10.1111\/dth.12848","article-title":"The efficacy of omalizumab in Cutaneous Mastocytosis: a case series","volume":"32","author":"Hinojosa","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2019.04.030_bib12","first-page":"52","article-title":"Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy","volume":"45","author":"Paraskevopoulos","year":"2013","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.04.030_bib13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2169\/internalmedicine.50.4640","article-title":"Omalizumab treatment of systemic mast cell activation disease: experiences from four cases","volume":"50","author":"Molderings","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.jaip.2019.04.030_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.04.030_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","article-title":"Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma","volume":"68","author":"Lowe","year":"2009","journal-title":"Br J Clin Pharmacol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819304349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819304349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:18:36Z","timestamp":1761974316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819304349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2213219819304349"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.04.030","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab and Mast Cell Disorders: Are We There Yet?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.03.039","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}